A Controlled Human Pneumococcal Infection Model (PIM) Study

Not Applicable

Completed

• Conditions: Streptococcus Pneumoniae Infection
• Interventions: Biological: Sp_6B; Drug: Amoxicillin 500 mg

• Registration Number: NCT05361499
• Lead Sponsor: Radboud University Medical Center

Brief Summary

Infection with Streptococcus pneumoniae (the pneumococcus) is the leading cause of pneumonia, bacterial meningitis and bacteraemia worldwide in the very young and the elderly. Although pneumococcal vaccines exist, they do not provide complete protection and new strategies to combat this pathogen are urgently needed. Asymptomatic infection of S. pneumoniae in the human nasopharynx precedes the development of pneumococcal disease. Previously, an Experimental Human Pneumococcal Carriage (EHPC) model has been developed at the Liverpool School of Tropical Medicine (LSTM). The current study entails to establish this model in healthy adults living in the Netherlands using the inoculation dose currently used at LSTM.

Healthy adult participants (M/F) will be inoculated intranasally with strain BHN418, a penicillin sensitive serotype 6B strain of S. pneumoniae that was previously isolated from a healthy carrier. Following inoculation, participants will be monitored and blood and nasal samples will be collected over a period of 28 ± 3 days. Participants will receive a course of amoxicillin to eradicate infection on or shortly after the last visit at day 28 ± 3, unless S. pneumoniae is not detected on both day 14 and 28 ± 3 post-inoculation.

Detailed Description

Not available

Study Timeline

• Status Verified: 2022-04
• Study First Submitted: 2022-04-29
• Study First Submitted QC: 2022-04-29
• Study First Posted: 2022-05-04
• Study Start: 2022-05-31
• Primary Completion: 2023-02-16
• Study Completion: 2023-02-16
• Last Update Submitted: 2023-02-21
• Last Update Posted: 2023-02-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

1. Participant is aged ≥ 18 and < 50 years on the day of the baseline visit.
2. Participant is in good health as confirmed by review of medical history and physical examination.
3. Participant has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
4. Participant has a home address within the Netherlands.
5. Participant is fully conversant in the Dutch language
6. Participant is able to communicate easily by both mobile telephone and text messaging
7. Participant is available to attend all study visits.
8. Participant agrees to inform his/her general practitioner (GP), in case applicable, about participation in the study and signs a request to release any relevant medical information concerning possible contra-indications for participation in the study by the GP.
9. Participant agrees to provide access to information regarding the vaccination background
10. Participant agrees to provide a treating physician access to all study-related information and data in case an adverse event occurs
11. Participant is able to arrive within 3h at the Radboudumc at any time during the study participation and participant is able to arrive within 1h at the Radboudumc from his/her home address. The participant must have a home address and live in the Netherlands.
12. Participant is willing to take an antibiotic regiment after inoculation with S. pneumoniae according to the study protocol.
13. Participant has signed informed consent.
14. Participant is able to answer all questions of the pre-consent questionnaire correctly.

Exclusion Criteria

1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results.

2. Smoking: Any smoking event in the last month, including (e-)cigarette, joint, cigar and pipe

3. Previous pneumococcal vaccination or infection with the pneumococcus at screening or inclusion visit

4. Close physical contact with at risk individuals, i.e. children under 5 years of age, immunosuppressed adults, frail elderly, chronically ill individuals. Close physical contact is defined as:

   • living in the same household
   • having work-related contact
   • spending more than 1 hour/day together with an at risk individual at less than 1.5 meter distance.

5. Illness at screening visit, illness at baseline (including mild upper respiratory tract infection, common cold, running nose), acute illness within 3 days prior to inoculation

6. Any antibiotic treatment within 2 weeks before inoculation

7. For female participants: pregnancy, lactation or intention to become pregnant during the study. Female volunteers are required to use an effective form of contraception during this study.

8. Known hypersensitivity to or contra-indications (including co-medication) for use of penicillin

9. Receipt of any vaccinations in the two weeks prior to the start of the study (inoculation) or plans to receive any other vaccinations during the study period.

10. Participation in any other clinical study (unless observational) in the three months prior to the start of the study or during the study period.

11. Being an employee or student of the department of Laboratory Medicine, Radboudumc.

12. Any other condition or situation that would, in the opinion of the investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Streptococcus pneumoniae 6B (Sp_6B) inoculated	Amoxicillin 500 mg	-
Streptococcus pneumoniae 6B (Sp_6B) inoculated	Sp_6B	-

Primary Outcome Measures

Name	Time	Method
Percentage of volunteers infected with S. pneumoniae serotype 6B following inoculation.	up to 4 weeks after inoculation

Secondary Outcome Measures

Name	Time	Method
The number of participants with sollicited AEs that are related to infection	from the baseline visit (between day -1 and -6) till the end of the study (day 28 ± 3)
Number of sampling timepoints with S. pneumoniae culture-positive nasal wash samples post-inoculation	On day 3, 7, 14 and 28 after inoculation
Concentrations of S. pneumoniae-specific antibodies in blood and mucosal samples at the various sampling time points	On day 3, 7, 14 and 28 after inoculation
The number, type and severity of sollicited AEs that are related to infection	from the baseline visit (between day -1 and -6) till the end of the study (day 28 ± 3)
Number of colony forming units (CFUs) per ml detected in nasal wash of infected participants at each sampling timepoint	On day 3, 7, 14 and 28 after inoculation

Trial Locations

Locations (1)

Radboudumc; 🇳🇱 Nijmegen, Netherlands